Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric lymphomas: overview and diagnostic challenges.

Virchows Archiv : an international journal of pathology·2024
Same author

Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young.

medRxiv : the preprint server for health sciences·2023
Same author

Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.

Clinics in laboratory medicine·2023
Same author

Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.

Clinics in laboratory medicine·2021
Same author

Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2021
Same author

Prospective randomized trial of interventions for vincristine-related neuropathic pain.

Pediatric blood & cancer·2020
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pediatric MLBL: challenges remain.

John T Sandlund1, John Kim Choi

  • 1St Jude Children's Research Hospital.

Blood
|January 12, 2013
PubMed
Summary
This summary is machine-generated.

Gerrard et al. report on mediastinal large B-cell lymphoma (MLBL) in pediatric patients, detailing outcomes and classifications. The study underscores the urgent need for novel therapeutic approaches for this rare cancer.

Related Experiment Videos

Last Updated: May 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Lymphoma Research

Background:

  • Mediastinal large B-cell lymphoma (MLBL) is a rare subtype of diffuse large B-cell lymphoma predominantly affecting young adults and adolescents.
  • Understanding the specific outcomes and histological characteristics of MLBL in pediatric populations is crucial for developing targeted therapies.

Purpose of the Study:

  • To analyze the clinical outcomes and provide detailed histologic classification of pediatric and adolescent patients diagnosed with mediastinal large B-cell lymphoma (MLBL).
  • To identify key factors influencing treatment response and survival in this specific patient cohort.
  • To emphasize the necessity for innovative treatment strategies tailored to MLBL in children and adolescents.

Main Methods:

  • Retrospective analysis of a cohort of children and adolescents diagnosed with MLBL.
  • Review of histopathologic features and diagnostic criteria for MLBL.
  • Evaluation of treatment regimens and patient outcomes, including response rates and survival data.

Main Results:

  • Detailed description of the histologic subtypes observed in pediatric MLBL cases.
  • Presentation of clinical outcomes, including event-free survival and overall survival rates.
  • Identification of prognostic indicators relevant to MLBL in the pediatric population.

Conclusions:

  • Mediastinal large B-cell lymphoma in children and adolescents exhibits distinct characteristics that warrant specific consideration.
  • Current treatment strategies may not be optimal for this subgroup, highlighting a critical need for research into new therapeutic options.
  • Further investigation into the biology and treatment of pediatric MLBL is essential to improve patient outcomes.